Text Size

Explanted Lung Tissues With Pulmonary Fibrosis

This study is currently recruiting participants.
Verified December 2012 by University of Chicago
Sponsor:
Information provided by (Responsible Party):
Sangeeta Bhorade, University of Chicago
ClinicalTrials.gov Identifier:
NCT00515567
First received: August 9, 2007
Last updated: December 24, 2012
Last verified: December 2012
History of Changes
  Purpose

The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.


Condition
Pulmonary Fibrosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Utilization of Explanted Lungs for Isolation of Tissue Samples and Primary Cell Lines to Study Pulmonary Fibrosis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • assess fibroblasts and cytokines associated with pulmonary fibrosis [ Time Frame: 12/2013 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

explanted lung tissue


Estimated Enrollment: 90
Study Start Date: February 2006
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Pulmonary Fibrosis involves scarring of the lung. Gradually, the air sacs of the lungs become replaced by fibrotic tissue. The most current thinking is that the fibrotic process is a reaction to tiny injury to the lung. When the scar forms, the tissue becomes thicker causing a permanent loss of the tissue's ability to carry oxygen into the bloodstream.

We need to obtain lung tissue from patients without pulmonary fibrosis and compare it to lung tissue from patients with pulmonary fibrosis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects listed for lung transplant

Criteria

Inclusion Criteria:

  • all patients awaiting lung transplant

Exclusion Criteria:

  • all who will not give consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00515567

Contacts
Contact: Lourdes Norwick, BSN, RN 773-834-8076 lnorwick@medicine.bsd.uchicago.edu

Locations
United States, Illinois
The University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Laura Krupa     773-834-8903     lkrupa@medicine.bsd.uchicago.edu    
Principal Investigator: Sangeeta Bhorade, MD            
Sub-Investigator: Nathan Sandbo, MD            
Sponsors and Collaborators
University of Chicago
Investigators
Principal Investigator: Sangeeta Bhorade, MD University of Chicago
  More Information

No publications provided

Responsible Party: Sangeeta Bhorade, Associate Professor, University of Chicago
ClinicalTrials.gov Identifier: NCT00515567     History of Changes
Other Study ID Numbers: 14514A
Study First Received: August 9, 2007
Last Updated: December 24, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
explanted lungs
pulmonary fibrosis

Additional relevant MeSH terms:
Fibrosis
Pulmonary Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 22, 2013